{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:19:02Z","timestamp":1769156342801,"version":"3.49.0"},"reference-count":22,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Tacrolimus, a calcineurin inhibitor (CNI), is the first-line treatment for chronic myeloid\nleukemia (CML) and advanced gastrointestinal stromal tumors (GIST). Imatinib and tacrolimus are both substrates\nof the hepatic enzymes CYP3A4\/5 and efflux transporter P-gp, so drug-drug interactions may occur during\ntheir co-administration treatment. Therefore, this study aimed to evaluate the pharmacokinetic interaction\nbetween imatinib and tacrolimus in rats.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Rats were divided into groups I (30 mg\/kg imatinib administered for 14 days), II (1.89 mg\/kg tacrolimus\nand 30 mg\/kg imatinib administered for 14 days), III (30mg\/kg imatinib and 0.63mg\/kg tacrolimus administered\nfor 14 days), IV (1.89mg\/kg tacrolimus for 14 days), and V (10mg\/kg imatinib and 1.89mg\/kg tacrolimus\nfor 14 days). Blood samples were determined for whole blood of tacrolimus, plasma of imatinib, and Ndesmethyl\nimatinib concentrations using ultra-performance liquid chromatography-mass spectrometry.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>After 1 day of a single dose, tacrolimus had no significant effect on the pharmacokinetics of imatinib\nand N-desmethyl imatinib; imatinib significantly increased the AUC and Cmax of tacrolimus (P &lt; 0.05). After\n14 days of multiple doses, tacrolimus significantly reduced the AUC and Cmax of imatinib and N-desmethyl\nimatinib (P &lt; 0.05). Further, imatinib significantly increased AUC0-24 and AUC0-\u221e of tacrolimus (P &lt; 0.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Imatinib increased tacrolimus blood concentrations after single and multiple administrations.\nTacrolimus did not significantly affect the pharmacokinetics of imatinib after a single dose; however, tacrolimus\nmight impact the absorption and metabolism of imatinib after multiple doses. The results showed that\nwhen imatinib and tacrolimus were co-administered, attention should be paid to the presence of drug-drug interactions.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892002319356241210073350","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T07:05:07Z","timestamp":1735023907000},"page":"613-621","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic Interaction between Imatinib and Tacrolimus in Rats"],"prefix":"10.2174","volume":"25","author":[{"given":"Naling","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, the Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy,\nShijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy,\nShijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy,\nShijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy,\nShijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinran","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Clinical Pharmacy,\nShijiazhuang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.trim.2009.07.001","volume":"22","author":"Rauch M.C.","year":"2009","unstructured":"Rauch M.C.; San Mart\u00edn A.; Ojeda D.; Quezada C.; Salas M.; C\u00e1rcamo J.G.; Ya\u00f1ez A.J.; Slebe J.C.; Claude A.; Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects. Transpl Immunol  2009,22(1-2),72-81","journal-title":"Transpl Immunol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","volume":"57","author":"Jusko W.J.","year":"1995","unstructured":"Jusko W.J.; Piekoszewski W.; Klintmalm G.B.; Shaefer M.S.; Hebert M.F.; Piergies A.A.; Lee C.C.; Schechter P.; Mekki Q.A.; Mekki Q.A.; Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther  1995,57(3),281-290","journal-title":"Clin Pharmacol Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1592\/phco.27.6.825","volume":"27","author":"Sansone-Parsons A.","year":"2007","unstructured":"Sansone-Parsons A.; Krishna G.; Martinho M.; Kantesaria B.; Gelone S.; Mant T.G.; Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy  2007,27(6),825-834","journal-title":"Pharmacotherapy"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1158\/1535-7163.MCT-05-0503","volume":"5","author":"Litz J.","year":"2006","unstructured":"Litz J.; Krystal G.W.; Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1\u03b1 activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther  2006,5(6),1415-1422","journal-title":"Mol Cancer Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"Kris M.G.","year":"2003","unstructured":"Kris M.G.; Natale R.B.; Herbst R.S.; Lynch T.J.; Prager D.; Belani C.P.; Schiller J.H.; Kelly K.; Spiridonidis H.; Sandler A.; Albain K.S.; Cella D.; Wolf M.K.; Averbuch S.D.; Ochs J.J.; Kay A.C.; Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA  2003,290(16),2149-2158","journal-title":"JAMA"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"Peng B.","year":"2005","unstructured":"Peng B.; Lloyd P.; Schran H.; Clinical pharmacokinetics of imatinib. Clin Pharmacokinet  2005,44(9),879-894","journal-title":"Clin Pharmacokinet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","volume":"53","author":"Bolton A.E.","year":"2004","unstructured":"Bolton A.E.; Peng B.; Hubert M.; Krebs-Brown A.; Capdeville R.; Keller U.; Seiberling M.; Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol  2004,53(2),102-106","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","volume":"54","author":"Dutreix C.","year":"2004","unstructured":"Dutreix C.; Peng B.; Mehring G.; Hayes M.; Capdeville R.; Pokorny R.; Seiberling M.; Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol  2004,54(4),290-294","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1159\/000538532","volume":"148","author":"Murt A.","year":"2024","unstructured":"Murt A.; Bayram B.; Y\u0131lmaz U.; Seyahi N.; E\u015fkazan A.E.; Chronic myeloid leukemia in renal transplantation patients in the era of tyrosine kinase inhibitors: A case report and review of the literature. Nephron J  2024,148(8),563-568","journal-title":"Nephron J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/ajt.16194","volume":"21","author":"Thiem U.","year":"2021","unstructured":"Thiem U.; Buxhofer-Ausch V.; Kranewitter W.; Webersinke G.; Enkner W.; Cejka D.; Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib. Am J Transplant  2021,21(1),405-409","journal-title":"Am J Transplant"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13318-023-00869-x","volume":"49","author":"Fan N.","year":"2024","unstructured":"Fan N.; Du L.; Guo T.; Liu M.; Chen X.; Pharmacokinetic interaction between imatinib and metformin in rats. Eur J Drug Metab Pharmacokinet  2024,49(2),171-179","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijpharm.2010.01.025","volume":"389","author":"Qin X.L.","year":"2010","unstructured":"Qin X.L.; Bi H.C.; Wang X.D.; Li J.L.; Wang Y.; Xue X.P.; Chen X.; Wang C.X.; Xu L.J.; Wang Y.T.; Huang M.; Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int J Pharm  2010,389(1-2),114-121","journal-title":"Int J Pharm"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"Christians U.","year":"2002","unstructured":"Christians U.; Jacobsen W.; Benet L.Z.; Lampen A.; Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet  2002,41(11),813-851","journal-title":"Clin Pharmacokinet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.3109\/03639045.2013.838582","volume":"40","author":"Lin G.","year":"2014","unstructured":"Lin G.; Wang C.; Qiu X.; Wang Z.; Han A.; Xu T.; Kan X.; Hu G.; Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm  2014,40(12),1616-1622","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","volume":"27","author":"Oostendorp R.L.","year":"2009","unstructured":"Oostendorp R.L.; Buckle T.; Beijnen J.H.; van Tellingen O.; Schellens J.H.M.; The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs  2009,27(1),31-40","journal-title":"Invest New Drugs"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/00001813-200310000-00011","volume":"14","author":"Wiedmann M.","year":"2003","unstructured":"Wiedmann M.; Kreth F.; Feisthammel J.; Deininger M.; M\u00f6ssner J.; Caca K.; Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? Anticancer Drugs  2003,14(9),751-760","journal-title":"Anticancer Drugs"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cpdd.132","volume":"4","author":"Bernard A.","year":"2015","unstructured":"Bernard A.; Vaccaro N.; Acharya M.; Jiao J.; Monbaliu J.; De Vries R.; Stieltjes H.; Yu M.; Tran N.; Chien C.; Impact on abiraterone pharmacokinetics and safety: Open\u2010label drug\u2013drug interaction studies with ketoconazole and rifampicin. Clin Pharmacol Drug Dev  2015,4(1),63-73","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1211\/jpp.58.7.0016","volume":"58","author":"Kajita T.","year":"2006","unstructured":"Kajita T.; Higashi Y.; Imamura M.; Maida C.; Fujii Y.; Yamamoto I.; Miyamoto E.; Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. J Pharm Pharmacol  2006,58(7),997-1000","journal-title":"J Pharm Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"Vanhove T.","year":"2016","unstructured":"Vanhove T.; Annaert P.; Kuypers D.R.J.; Clinical determinants of calcineurin inhibitor disposition: A mechanistic review. Drug Metab Rev  2016,48(1),88-112","journal-title":"Drug Metab Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"914842","DOI":"10.3389\/fphar.2022.914842","volume":"13","author":"Zhao T.","year":"2022","unstructured":"Zhao T.; Li X.; Chen Y.; Du J.; Chen X.; Wang D.; Wang L.; Zhao S.; Wang C.; Meng Q.; Sun H.; Liu K.; Wu J.; Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2\/3A4 and BCRP\/P-gp. Front Pharmacol  2022,13,914842","journal-title":"Front Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/lt.20500","volume":"11","author":"Ginsburg P.M.","year":"2005","unstructured":"Ginsburg P.M.; Thuluvath P.J.; Diarrhea in liver transplant recipients: Etiology and management. Liver Transpl  2005,11(8),881-890","journal-title":"Liver Transpl"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3389\/fimmu.2018.02649","volume":"9","author":"Duan Y.","year":"2018","unstructured":"Duan Y.; Zeng L.; Zheng C.; Song B.; Li F.; Kong X.; Xu K.; Inflammatory links between high fat diets and diseases. Front Immunol  2018,9,2649","journal-title":"Front Immunol"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002319356241210073350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/237536\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002319356241210073350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:05:49Z","timestamp":1741241149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/237536\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002319356241210073350","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}